醫生診室診斷市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品類型、應用、地區和競爭格局分類，2021-2031年）

全球醫師診間診斷市場預計將從 2025 年的 2.2934 億美元成長到 2031 年的 5.0632 億美元，複合年成長率為 14.11%。

這些診斷設備包括直接在醫師診療室使用的醫療檢測和系統，可提供即時結果，從而加速臨床決策。市場成長的主要促進因素是慢性病盛行率的上升、對快速診斷結果日益成長的需求以及醫療保健結構向分散化方向的轉變。日益加重的疾病負擔要求在基層醫療進行頻繁的監測和檢測，以便有效管理長期疾病。例如，國際糖尿病聯盟 (IDF) 報告稱，到 2024 年，全球約有 5.89 億成年人將患有糖尿病，這凸顯了在社區提供便利診斷解決方案的迫切需求。

然而，複雜的法規環境和報銷壓力嚴重阻礙了市場擴張。製造商必須遵守照護現場設備嚴格的核准程序，而醫療服務提供者則經常面臨較低的報銷率和嚴格的診內檢測應用限制。這些經濟和合規方面的障礙會抑制小規模診所採用新技術，並減緩全球診所診斷能力的整體提升。

市場促進因素

慢性病和文明病發生率的上升是全球臨床診斷市場的主要驅動力。隨著心血管疾病和糖尿病等疾病的日益普遍，基層醫療迫切需要持續、便捷的監測，以預防併發症。日益加重的疾病負擔促使診所採用診斷工具，使醫生能夠即時調整治療方案，從而減少患者就診次數。例如，雅培公司在2025年10月發布的「2025年第三季」財報中指出，持續血糖監測設備（對糖尿病這種文明病的管理至關重要）的銷售額成長了20.5%，達到20億美元，這表明人們對臨床監測技術的依賴性日益增強。

此外，快速、符合CLIA豁免照護現場設備的科技進步正在使複雜的檢測流程去中心化，從而加速市場成長。側向層析檢測和分子診斷技術的創新使得以往僅限於中心檢查室的高級檢測能夠在診所進行，顯著縮短了檢測結果的報告時間。這種轉變使得臨床決策能夠即時做出，並透過提供一站式醫療服務提高了患者滿意度。根據羅氏公司於2025年1月發布的“2024會計年度全年業績報告”，該公司核心診斷業務成長了8%，這得益於各領域對分子診斷和免疫診斷解決方案的強勁需求。同樣，Quest Diagnostics公司在2025年公佈的2024會計年度全年銷售額為98.7億美元，反映出診斷服務在整個醫療保健流程中持續維持著較高的利用率。

市場挑戰

複雜的監管環境和報銷限制嚴重限制了醫生診間診斷市場的擴張。製造商需要經過嚴格的照護現場設備核准流程，這不僅延緩了產品進入市場，也增加了研發成本。同時，醫療機構往往面臨報銷率下降和診室內檢測項目保險覆蓋範圍受限的困境。當保險支付無法涵蓋診斷設備的營運成本時，醫療機構便失去了採用這些技術的經濟獎勵，迫使許多基層醫療診所放棄投資建設內部檢測能力，轉而選擇外包檢測服務。

近期聯邦支付結構的調整進一步加劇了這些財務壓力，直接影響了醫療服務提供者的收入。據美國醫學會 (AMA) 稱，2024 年聯邦醫療保險醫師收費標準的轉換係數將比去年同期下降 3.37%。報銷水準的降低給醫療機構帶來了嚴峻的挑戰，他們必須在應對診斷合規和設備維護等高昂營運成本的同時，承受這些收入減少的影響。因此，這種財務不穩定限制了小規模醫療機構的購買力，並阻礙了診斷系統的整體普及。

市場趨勢

全球臨床診斷市場正經歷著向多重病原體檢測模式的轉變，這一趨勢正在重塑市場模式。此模式能夠從單一患者檢體同時檢測多種傳染性病原體。它正日益取代傳統的單靶點檢測，尤其是在呼吸道疾病領域，因為呼吸道合胞病毒（RSV）、流感和新冠病毒（COVID-19）的症狀經常重疊。採用整合檢測方案使基層醫療提供者能夠在一次就診中快速區分共同流行的病毒，從而簡化臨床工作流程並確保抗病毒藥物處方的準確性。主要企業的財務成功也印證了這個趨勢。根據丹納赫公司於2025年2月發布的《2024年第四季財報》，Sepeed公司的呼吸系統業務收入達到約5.5億美元，超出預期，這主要得益於分散式醫療機構對其四組分多重檢測產品的需求不斷成長。

同時，攜帶式診斷平台的微型化也提高了可在診療現場直接進行的醫學檢測的複雜性。製造商正在推出符合CLIA豁免標準的緊湊型設備，這些設備將先進的分子診斷功能整合到可放置在醫生診台或辦公桌上的小型設備中。這項技術進步使得即使是小規模診所也能避免在中心實驗室的物流延誤，並在幾分鐘內獲得檢查室級的檢測結果，從而支持即時治療決策。例如，生物梅里埃公司在2025年3月發布的2024年財務報告中指出，其緊湊型綜合症檢測平台SPOTFIRE系統的銷售額已達到9500萬歐元，遠超公司最初的年度目標，這便是這些解決方案迅速普及的一個例證。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球醫師診間診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類型（就地檢驗(POCT) 設備、臨床化學分析儀、免疫檢測系統、分子診斷、尿液分析系統）
  • 依應用領域（感染疾病、心血管疾病、代謝性疾病、癌症診斷、懷孕和不孕症檢測）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美醫師診間診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲醫師診間診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區醫師診間診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲醫生診室診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲醫師診間診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球醫師診間診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Sysmex America, Inc.
• Bio-Rad Laboratories, Inc.
• BioMerieux SA
• Beckman Coulter, Inc.
• Trinity Biotech Plc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Physician Office Diagnostic Market is projected to expand from USD 229.34 Million in 2025 to USD 506.32 Million by 2031, reflecting a CAGR of 14.11%. These diagnostics consist of medical tests and systems utilized directly within a doctor's clinic, offering immediate results that expedite clinical decision-making. The market's growth is primarily driven by the increasing prevalence of chronic diseases, a growing necessity for rapid diagnostic turnaround times, and a structural transition toward decentralized healthcare. This rising disease burden requires frequent monitoring and testing at the primary care level to effectively manage long-term conditions; for instance, the International Diabetes Federation reported that approximately 589 million adults globally were living with diabetes in 2024, underscoring the urgent need for accessible diagnostic solutions in community settings.

However, market expansion is significantly impeded by a complicated regulatory environment and reimbursement pressures. Manufacturers are required to navigate strict approval procedures for point-of-care devices, while healthcare providers frequently face reducing reimbursement rates or stringent coverage restrictions for in-office tests. These economic and compliance hurdles create disincentives for smaller practices to adopt new technologies, which can potentially decelerate the overall advancement of diagnostic capabilities in physician offices worldwide.

Market Driver

The rising incidence of chronic and lifestyle-related diseases acts as a major catalyst for the Global Physician Office Diagnostic Market. As conditions such as cardiovascular disorders and diabetes become more widespread, there is a critical need for consistent, accessible monitoring within primary care to avert complications. This increasing disease burden promotes the adoption of in-office diagnostic tools that enable practitioners to modify treatment plans in real-time, thereby decreasing the necessity for hospital visits. For example, Abbott reported in its 'Third Quarter 2025 Financial Results' in October 2025 that sales of continuous glucose monitors, which are essential for managing lifestyle-related diabetes, increased by 20.5% to reach $2 billion, demonstrating a deepened reliance on office-supported monitoring technologies.

Furthermore, technological advancements in rapid, CLIA-waived point-of-care devices are accelerating market growth by decentralizing complex testing procedures. Innovations in lateral flow assays and molecular diagnostics now permit physician offices to conduct sophisticated tests that were previously limited to central laboratories, significantly shortening turnaround times. This shift facilitates immediate clinical decision-making and improves patient satisfaction by offering one-stop medical services. Roche's January 2025 'Full Year 2024 Results' indicated that its Diagnostics Division's base business grew by 8%, fueled by robust demand for molecular and immunodiagnostic solutions in various settings. Similarly, Quest Diagnostics reported full-year 2024 revenues of $9.87 billion in 2025, reflecting the sustained high utilization of diagnostic services across the healthcare continuum.

Market Challenge

The expansion of the physician office diagnostic market is significantly restricted by a complex regulatory landscape combined with reimbursement constraints. Manufacturers endure rigorous approval processes for point-of-care devices, which delays market entry and escalates development costs. Simultaneously, healthcare providers often contend with declining reimbursement rates or strict coverage limitations for tests performed in the office. When insurance payments fail to cover the operational costs of diagnostic equipment, physician practices face a financial disincentive to adopt these technologies, forcing many primary care clinics to outsource testing rather than investing in on-site capabilities.

Recent adjustments in federal payment structures further evidence these financial pressures, directly affecting provider revenue. According to the American Medical Association, the Medicare Physician Fee Schedule conversion factor saw a reduction of 3.37 percent in 2024 compared to the prior year. Such cuts in reimbursement levels create a difficult environment for physician offices, which must absorb these reductions while managing the high overhead associated with maintaining diagnostic compliance and equipment. Consequently, this financial instability limits the purchasing power of smaller practices and hampers the overall adoption of diagnostic systems.

Market Trends

The Global Physician Office Diagnostic Market is being reshaped by a shift toward Syndromic Multiplex Pathogen Testing, which allows for the simultaneous detection of multiple infectious agents from a single patient sample. This method is replacing traditional single-target assays, especially for respiratory conditions where symptoms of RSV, influenza, and COVID-19 frequently overlap. By employing consolidated panels, primary care providers can rapidly distinguish between co-circulating viruses during a single visit, streamlining clinical workflows and ensuring accurate antiviral prescriptions. The financial success of major players highlights this trend; according to Danaher's February 2025 'Fourth Quarter 2024 Earnings Results,' Cepheid's respiratory revenue hit approximately $550 million, surpassing expectations due to strong demand for their 4-in-1 multiplex test in decentralized settings.

Simultaneously, the miniaturization of handheld diagnostic platforms is increasing the complexity of medical tests that can be performed directly at the point of care. Manufacturers are launching compact, CLIA-waived devices that condense sophisticated molecular capabilities into small-footprint instruments suitable for a clinic counter or doctor's desk. This technological evolution enables smaller practices to bypass the logistical delays of central reference laboratories, delivering lab-quality results within minutes to support immediate treatment decisions. Highlighting the rapid uptake of these solutions, bioMerieux reported in its March 2025 '2024 Financial Results' that sales of the SPOTFIRE system, a compact syndromic testing platform, reached €95 million, significantly outperforming the company's initial annual targets.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Sysmex America, Inc.
• Bio-Rad Laboratories, Inc.
• BioMerieux SA
• Beckman Coulter, Inc.
• Trinity Biotech Plc.

Report Scope

In this report, the Global Physician Office Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Physician Office Diagnostic Market, By Product Type

• Point-of-Care Testing (POCT) Devices
• Clinical Chemistry Analyzers
• Immunoassay Systems
• Molecular Diagnostics
• Urinalysis Systems

Physician Office Diagnostic Market, By Application

• Infectious Diseases
• Cardiovascular Disorders
• Metabolic Disorders
• Cancer Diagnosis
• Pregnancy
• Fertility Testing

Physician Office Diagnostic Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Physician Office Diagnostic Market.

Available Customizations:

Global Physician Office Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Physician Office Diagnostic Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Point-of-Care Testing (POCT) Devices, Clinical Chemistry Analyzers, Immunoassay Systems, Molecular Diagnostics, Urinalysis Systems)
  • 5.2.2. By Application (Infectious Diseases, Cardiovascular Disorders, Metabolic Disorders, Cancer Diagnosis, Pregnancy, Fertility Testing)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Physician Office Diagnostic Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Physician Office Diagnostic Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Physician Office Diagnostic Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Physician Office Diagnostic Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application

7. Europe Physician Office Diagnostic Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Physician Office Diagnostic Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Physician Office Diagnostic Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Physician Office Diagnostic Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Physician Office Diagnostic Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Physician Office Diagnostic Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Physician Office Diagnostic Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Physician Office Diagnostic Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Physician Office Diagnostic Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Physician Office Diagnostic Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Physician Office Diagnostic Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Physician Office Diagnostic Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Physician Office Diagnostic Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Physician Office Diagnostic Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Physician Office Diagnostic Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Physician Office Diagnostic Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application

10. South America Physician Office Diagnostic Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Physician Office Diagnostic Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Physician Office Diagnostic Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Physician Office Diagnostic Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Physician Office Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Siemens Healthineers AG
• 15.3. Abbott Laboratories Inc.
• 15.4. Thermo Fisher Scientific Inc.
• 15.5. Danaher Corporation
• 15.6. Sysmex America, Inc.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. BioMerieux SA
• 15.9. Beckman Coulter, Inc.
• 15.10. Trinity Biotech Plc.

16. Strategic Recommendations

17. About Us & Disclaimer